Pyxis Oncology, Inc. Operating Lease, Payments
Pyxis Oncology, Inc. (PYXS) reported Operating Lease, Payments of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-13
- Pyxis Oncology, Inc. operating lease, payments for the quarter ending 2026-06-30 was $800.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. operating lease, payments for the quarter ending 2026-03-31 was $800.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. operating lease, payments for the quarter ending 2025-12-31 was $859.00K, a 4.02% decline year-over-year.
- Pyxis Oncology, Inc. operating lease, payments for the quarter ending 2025-09-30 was $800.00K, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. operating lease, payments for fiscal 2025 was $3.36M, a 1.94% increase from fiscal 2024.
- Pyxis Oncology, Inc. operating lease, payments for fiscal 2024 was $3.29M, a 30.96% increase from fiscal 2023.
- Pyxis Oncology, Inc. operating lease, payments for fiscal 2023 was $2.52M, a 279.49% increase from fiscal 2022.
- Pyxis Oncology, Inc. operating lease, payments for fiscal 2022 was $663.00K, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-13 | $1.70M 10-Q · filed 2026-08-13 | $2.46M derived: sum of 3 quarters · filed 2026-08-13 | $3.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-14 | $1.66M derived: sum of 2 quarters · filed 2026-05-14 | $2.46M derived: sum of 3 quarters · filed 2026-05-14 | $3.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $859.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.66M derived: sum of 2 quarters · filed 2026-03-23 | $2.46M derived: sum of 3 quarters · filed 2026-08-13 | $3.36M 10-K · filed 2026-03-23 |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-03 | $1.60M derived: sum of 2 quarters · filed 2026-08-13 | $2.50M 10-Q · filed 2025-11-03 | $3.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $800.00K 10-Q · filed 2026-08-13 | $1.60M 10-Q · filed 2026-08-13 | $2.50M derived: sum of 3 quarters · filed 2026-08-13 | $3.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $800.00K 10-Q · filed 2026-05-14 | $1.70M derived: sum of 2 quarters · filed 2026-05-14 | $2.50M derived: sum of 3 quarters · filed 2026-05-14 | $3.29M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $895.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.70M derived: sum of 2 quarters · filed 2026-03-23 | $2.50M derived: sum of 3 quarters · filed 2026-03-23 | $3.29M 10-K · filed 2026-03-23 |
| 2024-09-30 | $800.00K 10-Q · filed 2025-11-03 | $1.60M derived: sum of 2 quarters · filed 2025-11-03 | $2.40M 10-Q · filed 2025-11-03 | $3.52M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-14 | $1.60M 10-Q · filed 2025-08-14 | $2.72M derived: sum of 3 quarters · filed 2025-08-14 | $3.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.10M 10-Q · filed 2025-05-15 | $1.92M derived: sum of 2 quarters · filed 2025-05-15 | $2.42M derived: sum of 3 quarters · filed 2025-05-15 | $3.42M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $816.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.32M derived: sum of 2 quarters · filed 2025-03-18 | $2.32M derived: sum of 3 quarters · filed 2025-03-18 | $2.52M 10-K · filed 2025-03-18 |
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.50M derived: sum of 2 quarters · filed 2024-11-12 | $1.70M 10-Q · filed 2024-11-12 | $1.06M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.20M 10-Q · filed 2024-08-14 | $563.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.26M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-14 | -$437.00K derived: sum of 2 quarters · filed 2024-05-14 | $263.00K derived: sum of 3 quarters · filed 2024-05-14 | $663.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$637.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $63.00K derived: sum of 2 quarters · filed 2024-03-21 | $463.00K derived: sum of 3 quarters · filed 2024-03-21 | $663.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.10M derived: sum of 2 quarters · filed 2023-11-07 | $1.30M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $600.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $663.00K 10-K · filed 2023-03-22 | |||
| 2020-12-31 | $484.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |